The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary

first line therapy

Jan 16, 2006

when i found out my hiv status, my t cell count was 189 and v.l was 34,000. i had no symptoms. my doc started me on sustiva, viread and epivir. v.l. was 250 in just 3 weeks, one year later ive been undetectable for 1110 months and t cell at 380. my question is , none of your site info states my 3 meds are a good first line .can you shed some light? also i have had no side effects except some "foggyness" (sustiva) but i just take that at night. im just nervous about failure... thanks

Response from Dr. Pierone

Hello and thanks for posting. It sounds like you are doing very well on therapy, keep up the great work. This regimen that you are on is actually quite commonly used first line with excellent results. Truvada (Viread + Emtriva) has supplanted Epivir and Viread for many patients that are starting therapy now because it is one pill instead of two. The risk of failure of the regimen you are on is very low as long as adherence is good. Best of luck to you!

Neurological symptoms. What's going on?
videx and diabeters

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint